This product is discontinued due to commercial reason. Cenobamate (Xcopri), formerly known as YKP-3089, is a novel antiepileptic drug for the treatment of partial-onset seizures in adults. Cenobamate showed broad-spectrum anticonvulsant activity. In November 2019, the U.S. Food and Drug Administration (FDA) approved cenobamate, and granted the application for Xcopri to SK Life Science Inc. Cenobamate is a voltage-gated sodium channel (VGSC) blocker. It is a selective blocker of the inactivated state of VGSCs, preferentially inhibiting persistent sodium current. It has been proposed that cenobamate additionally enhances presynaptic release of γ-aminobutyric acid (GABA), thereby increasing inhibitory GABAergic neurotransmission

纯度：≥98%

CAS：913088-80-9